news

NICE does not recommend polatuzumab vedotin to treat lymphoma

7
SHARES

NICE has formed a negative opinion for Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine to treat diffuse large B-cell lymphoma.

Lymphoma cells

The UK National Institute for Health and Care Excellence (NICE) has announced its publication of draft guidance that does not recommend Roche’s Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine. The organisation has rejected an application that the treatment be recommended for adults with diffuse large B-cell lymphoma (DLBCL) that has relapsed or not responded to primary treatment and who cannot have a haematopoietic stem cell transplant.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

Clinical trial evidence showed that the cancer became undetectable in around 40 percent of patients treated with polatuzumab vedotin with rituximab and bendamustine, compared with around 18 percent of patients treated with rituximab and bendamustine alone. Evidence also suggests that the combination treatment increases progression-free survival and overall survival compared with rituximab and bendamustine alone. However, there is substantial uncertainty in the submitted data.

The company submission lacks strong long-term evidence on remission with the treatment and the NICE committee found flaws in the methods used to calculate the background mortality, which led to unreliable results. Additionally, the organisation says that limitations in the data created uncertainty around the cost-effectiveness, leading to the negative decision. 

…there is substantial uncertainty in the submitted data”

Consultees now have the opportunity to comment on the released draft recommendations until 18 March 2020, NICE has announced. 

The draft guidance can be found here

Share via
Share via